{"nctId":"NCT00399035","briefTitle":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","startDateStruct":{"date":"2006-11"},"conditions":["Metastatic Colorectal Cancer"],"count":1254,"armGroups":[{"label":"FOLFOX + placebo Cediranib","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)","Drug: Cediranib Placebo"]},{"label":"Xelox + placebo Cediranib","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: XELOX (Capecitabine and Oxaliplatin)","Drug: Cediranib Placebo"]},{"label":"FOLFOX + Cediranib","type":"EXPERIMENTAL","interventionNames":["Drug: Cediranib","Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)"]},{"label":"XELOX + Cediranib","type":"EXPERIMENTAL","interventionNames":["Drug: Cediranib","Drug: XELOX (Capecitabine and Oxaliplatin)"]}],"interventions":[{"name":"Cediranib","otherNames":["AZD2171","RECENTIN™"]},{"name":"FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)","otherNames":["Other Names:","5-FU","Drug: Leucovorin (in FOLFOX)","intravenous infusion","Drug: Oxaliplatin (in FOLFOX)","Eloxatin®"]},{"name":"XELOX (Capecitabine and Oxaliplatin)","otherNames":["Xeloda® + Eloxatin®"]},{"name":"Cediranib Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written Informed Consent\n* Carcinoma of the colon or rectum\n* One or more measurable lesions\n\nExclusion Criteria:\n\n* Adjuvant/neoadjuvant therapy within 6-12 months of study entry\n* Untreated unstable brain or meningeal metastases\n* Specific laboratory ranges\n* Specific cardiovascular problems\n* Participation in other trials within 30 days","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival","description":"RECIST criteria defined as follows: Target lesions Complete Response (CR) Disappearance of all target lesions Partial Response (PR) At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD.Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Non-target lesions Complete Response (CR) Disappearance of all non-target lesions Non-Complete Response (non-CR/Non- Progression \\[non-PD\\]) Persistence of one or more non-target lesion or/and maintenance of tumour marker level above the normal limits. Progression (PD) Unequivocal progression of existing nontarget lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"8.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival","description":"Number of months from randomisation to the date of death from any cause","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":null},{"groupId":"OG001","value":"18.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate","description":"Objective tumour response(defined as a confirmed response of CR or PR).The definition for a confirmed response was met when an initial RECIST response of PR/CR was confirmed at the next scheduled visit as a PR/CR according to an evaluable assessment.Intervening assessments of non-evaluable or stable disease were allowable as long as the initial RECIST response was confirmed.RECIST criteria defined as follows: Target lesions Complete Response(CR)Disappearance of all target lesions Partial Response (PR).At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.Non-target lesions Complete Response (CR) Disappearance of all non-target lesi","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"254","spread":null},{"groupId":"OG001","value":"178","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Percentage Change in Tumour Size","description":"Maximum percentage reduction or minimum percentage increase in tumour size where size is the sum of the longest diameters of the target lesions","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.49","spread":"28.139"},{"groupId":"OG001","value":"-40.61","spread":"31.992"}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Based on RECIST measurements taken throughout the study and best objective tumour response at the defined analysis cut-off point. Measured from the time the criteria for CR/PR are first met (whichever is recorded first) until the patient progresses or dies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"6.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Resection of Liver Metastases","description":"Number of patients undergoing liver resection, based on patients with liver disease at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Wound Healing Complications","description":"Number of days from post-randomisation surgery until wound healing complications","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":94,"n":214},"commonTop":["Diarrhoea","Nausea","Decreased Appetite","Vomiting","Fatigue"]}}}